Patents by Inventor Vivek Sasikumar

Vivek Sasikumar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dual-acting antihypertensive agents
    Patent number: 8735625
    Abstract: The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: May 27, 2014
    Assignee: Theravance, Inc.
    Inventors: Seok-ki Choi, Paul R. Fatheree, Ryan Hudson, Keith Jendza, Robert Murray McKinnell, Vivek Sasikumar
  • DUAL-ACTING ANTIHYPERTENSIVE AGENTS
    Publication number: 20140046075
    Abstract: The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.
    Type: Application
    Filed: January 31, 2013
    Publication date: February 13, 2014
    Applicant: THERAVANCE, INC.
    Inventors: Seok-ki Choi, Paul R. Fatheree, Ryan Hudson, Keith Jendza, Robert Murray McKinnell, Vivek Sasikumar
  • Dual-acting antihypertensive agents
    Patent number: 8394846
    Abstract: The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: March 12, 2013
    Assignee: Theravance, Inc.
    Inventors: Seok-Ki Choi, Paul R. Fatheree, Ryan Hudson, Keith Jendza, Robert Murray McKinnell, Vivek Sasikumar
  • Dual-acting antihypertensive agents
    Patent number: 8236839
    Abstract: The invention relates to compounds having the formula: wherein: Ar, r, R3, Z, X, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: August 7, 2012
    Assignee: Theravance, Inc.
    Inventors: Seok-Ki Choi, Paul R. Fatheree, Roland Gendron, Ryan Hudson, Robert Murray McKinnell, Vivek Sasikumar
  • DUAL-ACTING ANTIHYPERTENSIVE AGENTS
    Publication number: 20120129900
    Abstract: The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.
    Type: Application
    Filed: January 30, 2012
    Publication date: May 24, 2012
    Applicant: THERAVANCE, INC.
    Inventors: Seok-Ki CHOI, Paul R. FATHEREE, Sharath HEGDE, Ryan HUDSON, Keith JENDZA, Daniel MARQUESS, Robert M. MCKINNELL, Vivek SASIKUMAR
  • DUAL-ACTING ANTIHYPERTENSIVE AGENTS
    Publication number: 20120088919
    Abstract: The invention relates to compounds having the formula: wherein: Ar, r, R3, Z, X, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Application
    Filed: December 19, 2011
    Publication date: April 12, 2012
    Applicant: THERAVANCE, INC.
    Inventors: Seok-Ki CHOI, Paul R. FATHEREE, Roland GENDRON, Ryan HUDSON, Robert Murray MCKINNELL, Vivek SASIKUMAR
  • Dual-acting antihypertensive agents
    Patent number: 8143298
    Abstract: The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: March 27, 2012
    Assignee: Theravance, Inc.
    Inventors: Seok-Ki Choi, Paul R. Fatheree, Ryan Hudson, Keith Jendza, Robert Murray McKinnell, Vivek Sasikumar
  • Dual-acting antihypertensive agents
    Patent number: 8106082
    Abstract: The invention relates to compounds having the formula: wherein: Ar, r, R3, Z, X, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: January 31, 2012
    Assignee: Theravance, Inc.
    Inventors: Seok-Ki Choi, Paul R. Fatheree, Roland Gendron, Ryan Hudson, Robert Murray McKinnell, Vivek Sasikumar
  • Amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof
    Patent number: 8067455
    Abstract: The present invention provides a prodrug of propofol and crystalline forms thereof, methods of making the propofol prodrug and crystalline forms thereof, pharmaceutical compositions of the propofol prodrug and crystalline forms thereof, methods of using the propofol prodrug and crystalline forms thereof and pharmaceutical compositions thereof to treat diseases or disorders such as headache pain, post-chemotherapy or post-operative surgery nausea and vomiting, neurodegenerative disorders, and mood disorders.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: November 29, 2011
    Assignee: XenoPort, Inc.
    Inventors: Feng Xu, Mark A. Gallop, Vivek Sasikumar, Usha Dilip
  • DUAL-ACTING ANTIHYPERTENSIVE AGENTS
    Publication number: 20110021585
    Abstract: The invention relates to compounds having the formula: wherein: Ar, r, R3, Z, X, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Application
    Filed: October 6, 2010
    Publication date: January 27, 2011
    Applicant: THERAVANCE, INC.
    Inventors: Seok-Ki CHOI, Paul R. FATHEREE, Roland GENDRON, Ryan HUDSON, Robert Murray MCKINNELL, Vivek SASIKUMAR
  • Dual-acting antihypertensive agents
    Patent number: 7834041
    Abstract: The invention relates to compounds having the formula: wherein: Ar, r, R3, Z, X, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: November 16, 2010
    Assignee: Theravance, Inc.
    Inventors: Seok-Ki Choi, Paul R. Fatheree, Roland Gendron, Ryan Hudson, Robert Murray McKinnell, Vivek Sasikumar
  • DUAL-ACTING ANTIHYPERTENSIVE AGENTS
    Publication number: 20100267788
    Abstract: The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.
    Type: Application
    Filed: June 30, 2010
    Publication date: October 21, 2010
    Applicant: THERAVANCE, INC.
    Inventors: Seok-Ki CHOI, Paul R. FATHEREE, Sharath HEGDE, Ryan HUDSON, Keith JENDZA, Daniel MARQUESS, Robert M. McKINNELL, Vivek SASIKUMAR
  • Dual-acting antihypertensive agents
    Patent number: 7777077
    Abstract: The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.
    Type: Grant
    Filed: January 31, 2008
    Date of Patent: August 17, 2010
    Assignee: Theravance, Inc.
    Inventors: Seok-Ki Choi, Paul R. Fatheree, Ryan Hudson, Keith Jendza, Robert M. McKinnell, Vivek Sasikumar
  • AMINO ACID DERIVED PRODRUGS OF PROPOFOL, COMPOSITIONS, USES AND CRYSTALLINE FORMS THEREOF
    Publication number: 20100087536
    Abstract: The present invention provides a prodrug of propofol and crystalline forms thereof, methods of making the propofol prodrug and crystalline forms thereof, pharmaceutical compositions of the propofol prodrug and crystalline forms thereof, methods of using the propofol prodrug and crystalline forms thereof and pharmaceutical compositions thereof to treat diseases or disorders such as headache pain, post-chemotherapy or post-operative surgery nausea and vomiting, neurodegenerative disorders, and mood disorders.
    Type: Application
    Filed: October 2, 2009
    Publication date: April 8, 2010
    Applicant: XenoPort, Inc.
    Inventors: Feng Xu, Mark A. Gallop, Vivek Sasikumar, Usha Dilip
  • AMINO ACID DERIVED PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF
    Publication number: 20090286763
    Abstract: The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting.
    Type: Application
    Filed: May 18, 2009
    Publication date: November 19, 2009
    Applicant: XenoPort, Inc.
    Inventors: Feng Xu, Mark A. Gallop, Vivek Sasikumar
  • Amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof
    Patent number: 7619110
    Abstract: The present invention provides a prodrug of propofol and crystalline forms thereof, methods of making the propofol prodrug and crystalline forms thereof, pharmaceutical compositions of the propofol prodrug and crystalline forms thereof, methods of using the propofol prodrug and crystalline forms thereof and pharmaceutical compositions thereof to treat diseases or disorders such as headache pain, post-chemotherapy or post-operative surgery nausea and vomiting, neurodegenerative disorders, and mood disorders.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: November 17, 2009
    Assignee: XenoPort, Inc.
    Inventors: Feng Xu, Mark A. Gallop, Vivek Sasikumar, Usha Dilip
  • Amino acid derived prodrugs of propofol, compositions and uses thereof
    Patent number: 7550506
    Abstract: The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting.
    Type: Grant
    Filed: July 12, 2005
    Date of Patent: June 23, 2009
    Assignee: XenoPort, Inc.
    Inventors: Feng Xu, Mark A. Gallop, Vivek Sasikumar
  • Dual-acting antihypertensive agents
    Publication number: 20090093417
    Abstract: The invention relates to compounds having the formula: wherein: Ar, r, R3, Z, X, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Application
    Filed: September 5, 2008
    Publication date: April 9, 2009
    Inventors: Seok-Ki Choi, Paul R. Fatheree, Roland Gendron, Ryan Hudson, Robert Murray McKinnell, Vivek Sasikumar
  • Dual-acting antihypertensive agents
    Publication number: 20080188533
    Abstract: The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.
    Type: Application
    Filed: January 31, 2008
    Publication date: August 7, 2008
    Inventors: Seok-Ki Choi, Paul R. Fatheree, Sharath Hegde, Ryan Hudson, Keith Jendza, Daniel Marquess, Robert M. McKinnel, Vivek Sasikumar
  • Amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof
    Publication number: 20060205969
    Abstract: The present invention provides a prodrug of propofol and crystalline forms thereof, methods of making the propofol prodrug and crystalline forms thereof, pharmaceutical compositions of the propofol prodrug and crystalline forms thereof, methods of using the propofol prodrug and crystalline forms thereof and pharmaceutical compositions thereof to treat diseases or disorders such as headache pain, post-chemotherapy or post-operative surgery nausea and vomiting, neurodegenerative disorders, and mood disorders.
    Type: Application
    Filed: December 22, 2005
    Publication date: September 14, 2006
    Inventors: Feng Xu, Mark Gallop, Vivek Sasikumar, Usha Dilip